AbCellera Biologics Inc. (NASDAQ:ABCL) CEO Sells $144,780,000.00 in Stock

AbCellera Biologics Inc. (NASDAQ:ABCL) CEO Carl L. G. Hansen sold 6,000,000 shares of AbCellera Biologics stock in a transaction on Wednesday, June 9th. The stock was sold at an average price of $24.13, for a total value of $144,780,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of NASDAQ ABCL traded up $1.00 during mid-day trading on Thursday, hitting $24.84. The stock had a trading volume of 3,594,464 shares, compared to its average volume of 1,093,978. The stock’s 50 day moving average price is $29.11. AbCellera Biologics Inc. has a twelve month low of $23.20 and a twelve month high of $71.91. The stock has a market cap of $6.73 billion and a price-to-earnings ratio of 54.31.

AbCellera Biologics (NASDAQ:ABCL) last announced its quarterly earnings results on Wednesday, May 12th. The company reported $0.37 earnings per share for the quarter, hitting the consensus estimate of $0.37. The company had revenue of $202.74 million for the quarter, compared to analyst estimates of $199.43 million. As a group, sell-side analysts forecast that AbCellera Biologics Inc. will post 0.44 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of the business. SB Management Ltd lifted its position in shares of AbCellera Biologics by 15.5% during the 1st quarter. SB Management Ltd now owns 7,817,190 shares of the company’s stock worth $265,472,000 after purchasing an additional 1,050,000 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in shares of AbCellera Biologics in the first quarter valued at about $532,000. Paloma Partners Management Co purchased a new stake in shares of AbCellera Biologics in the first quarter valued at about $903,000. Canada Pension Plan Investment Board purchased a new position in shares of AbCellera Biologics during the first quarter valued at approximately $4,245,000. Finally, Morgan Stanley raised its stake in AbCellera Biologics by 2,353.1% during the first quarter. Morgan Stanley now owns 72,365 shares of the company’s stock worth $2,458,000 after purchasing an additional 69,415 shares during the period. Institutional investors and hedge funds own 26.09% of the company’s stock.

Several brokerages recently commented on ABCL. SVB Leerink cut their price objective on AbCellera Biologics from $52.00 to $45.00 and set an “outperform” rating for the company in a report on Tuesday, March 30th. Credit Suisse Group decreased their target price on AbCellera Biologics from $53.00 to $51.00 and set an “outperform” rating on the stock in a research report on Friday, May 14th. BMO Capital Markets reduced their price objective on AbCellera Biologics from $61.00 to $59.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 24th. Berenberg Bank reissued a “buy” rating and set a $53.00 price objective on shares of AbCellera Biologics in a research note on Tuesday, March 30th. Finally, Stifel Nicolaus cut their target price on AbCellera Biologics from $59.00 to $55.00 and set a “buy” rating on the stock in a research note on Tuesday, March 30th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $52.60.

AbCellera Biologics Company Profile

AbCellera Biologics Inc develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract.

Further Reading: Most Active Stocks

Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.